CervoMed provides update on neflamapimod DLB program

CervoMed (CRVO) provided an update on its neflamapimod development program in dementia with Lewy bodies, DLB, as part of an oral presentation at the 8th International Lewy Body Dementia Conference of the topline results for the blinded portion of the Company’s Phase 2b RewinD-LB trial. Key Findings from RewinD-LB Trial: No discernible differences between neflamapimod 40mg dosed three times daily and placebo treatment groups during the 16-week double-blind phase of the clinical study; Measured trough plasma drug concentrations during the double-blind phase were, on average, similar to those seen with 40mg twice-daily dosing in a previous study in Alzheimer’s Disease; Retrospective analysis of the capsules suggests the lower-than-expected bioavailability may be related primarily to the age of the drug batch utilized during the double-blind phase of the study; The Company believes there is potential to obtain efficacy endpoint data at the targeted plasma drug concentrations during the open-label extension phase of the study; Pharmacokinetic findings from a food effect study in healthy volunteers conducted in 4Q 2024 with the newer capsules and within-subject comparison of 13 participants during the OLE phase each indicate that, on average, participants achieved target plasma concentrations with the newer capsules; Topline data from the first 16 weeks of the OLE phase of the RewinD-LB trial are expected in 1Q 2025.